WCM Investment Management LLC Boosts Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

WCM Investment Management LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,135,857 shares of the company's stock after purchasing an additional 104,733 shares during the period. WCM Investment Management LLC owned about 0.09% of Novo Nordisk A/S worth $286,615,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Harbour Trust & Investment Management Co increased its stake in Novo Nordisk A/S by 26.1% in the first quarter. Harbour Trust & Investment Management Co now owns 107,261 shares of the company's stock valued at $7,448,000 after purchasing an additional 22,195 shares during the last quarter. Pictet North America Advisors SA lifted its position in shares of Novo Nordisk A/S by 28.6% during the 1st quarter. Pictet North America Advisors SA now owns 72,154 shares of the company's stock worth $5,010,000 after buying an additional 16,030 shares during the last quarter. DAVENPORT & Co LLC boosted its holdings in shares of Novo Nordisk A/S by 61.1% in the 1st quarter. DAVENPORT & Co LLC now owns 1,695,522 shares of the company's stock valued at $117,682,000 after buying an additional 642,810 shares in the last quarter. Impact Investors Inc grew its position in shares of Novo Nordisk A/S by 14.1% in the 1st quarter. Impact Investors Inc now owns 5,698 shares of the company's stock valued at $396,000 after buying an additional 704 shares during the last quarter. Finally, Mather Group LLC. raised its stake in Novo Nordisk A/S by 6.2% during the 1st quarter. Mather Group LLC. now owns 5,933 shares of the company's stock worth $412,000 after acquiring an additional 345 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NVO stock traded down $0.77 during trading on Friday, hitting $69.05. The company had a trading volume of 4,047,911 shares, compared to its average volume of 7,246,407. The firm has a 50-day moving average price of $69.82 and a 200-day moving average price of $76.19. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The firm has a market cap of $308.31 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $143.69.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion for the quarter. On average, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Finally, BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.